Lindbrook Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Lindbrook Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$6.83K	Buy	129 +3	+2%	+$166	﹤0.01%	1821
2024 Q4	$7.05K	Hold	126	–	–	﹤0.01%	1825
2024 Q3	$6.6K	Hold	126	–	–	﹤0.01%	1887
2024 Q2	$5.17K	Buy	126 +29	+30%	+$1.16K	﹤0.01%	1975
2024 Q1	$4.2K	Hold	97	–	–	﹤0.01%	1969
2023 Q4	$4.46K	Buy	97 +38	+64%	+$1.2K	﹤0.01%	1944
2023 Q3	$1.35K	Buy	+59	New	+$1.32K	﹤0.01%	2265
2022 Q2	–	Sell	-443	Closed	-$5K	–	2732
2022 Q1	$5K	Buy	443 +360	+434%	+$3.16K	﹤0.01%	1610
2021 Q4	$1K	Buy	+83	New	+$932	﹤0.01%	1987
2021 Q2	–	Sell	-47	Closed	-$1K	–	1995
2021 Q1	$1K	Hold	47	–	–	﹤0.01%	1785
2020 Q4	$1K	Hold	47	–	–	﹤0.01%	1682
2020 Q3	$1K	Hold	47	–	–	﹤0.01%	1637
2020 Q2	$1K	Sell	47 -8	-15%	-$156	﹤0.01%	1618
2020 Q1	$1K	Buy	+55	New	+$985	﹤0.01%	1541

Other funds holding RYTM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lindbrook Capital's RYTM Position: Q1 2025 in Review

Lindbrook Capital increased its Rhythm Pharmaceuticals (RYTM) stake by 2.4% in Q1 2025, buying an estimated $166 and bringing the position to 129 shares worth $6.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

Lindbrook Capital first reported a position in RYTM in Q1 2020 and has held it in 14 quarters since. The position peaked at $7.05K in Q4 2024. 228 funds tracked by Wall St. Rank hold RYTM as of Q1 2025.

Lindbrook Capital held 129 shares of Rhythm Pharmaceuticals worth $6.83K as of Q1 2025.
Lindbrook Capital bought 3 Rhythm Pharmaceuticals shares in Q1 2025, an estimated $166.
Rhythm Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1821 holding.
Lindbrook Capital first reported a position in Rhythm Pharmaceuticals in Q1 2020 and has held it in 14 quarters since.
Lindbrook Capital's Rhythm Pharmaceuticals position peaked at $7.05K in Q4 2024.
228 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.